B cell aplasia, as characterized by the elimination and absence of B cells, is a renowned off-tumor incident after CD19- or CD22-based CAR T cell therapy mediating hypogammaglobulinemia in the recipients that subjects them to various types of infectious diseases (30, 64). This evidence concerns the gene CD19 and neoplasm.